Adaptimmune and TCR2 Therapeutics, two clinical-stage biotechs that have recently cut staff to conserve capital, are coming together in a deal that aligns their cell therapy strategies. The business combination also extends the new…
Continue Reading
The FDA has accepted Eisai’s application seeking full approval for its Alzheimer’s disease drug, setting a summer date for a regulatory decision that could smooth the path for insurance companies to begin coverage for…
Continue Reading
Chroma Medicine, a biotech company developing therapies that turn genes on or off as a way of treating genetic disorders, has raised $135 million as it works to generate data that could show the…
Continue Reading
The healthcare industry is continuing to evolve with technological innovations that can provide clinicians with a more holistic view of their patient’s health and which we ultimately expect to improve patient outcomes. Both telehealth…
Continue Reading
Patients whose blood cancer advances after initial treatments have one last therapeutic option: the engineering of their immune cells into a living medicine. But cancer is crafty and it often finds a way to…
Continue Reading
Life-sciences companies faced fewer class-action securities lawsuits last year, continuing a trend of declining litigation over the last few years, according to a report published in February by the law firm Dechert LLP.Investors filed…
Continue Reading
The pain drug market has many products, but there’s still a need for pills with better properties, such as avoiding addiction. Eli Lilly sees potential in the non-opioid pain drug research from Confo Therapeutics…
Continue Reading
Liz Kost, an employee at soap company Dr. Bronner’s, was stuck in a difficult place mentally after the Covid-19 pandemic hit. She tried traditional forms of therapy, such as talk therapy, but it was…
Continue Reading
MorphoSys, a company whose research has yielded programs placed with big pharmaceutical companies and upstart biotechs, is stopping all preclinical work to focus on cancer, particularly a late-stage drug candidate it acquired in a…
Continue Reading
As a health economist, researcher in evidence-based medicine, and consultant to biopharma executives, I am no stranger to data. We all want more of it, to make sense of it, and to use it…
Continue Reading
